University of Groningen
Access to innovative medicines in a middle-income country
Moye Holz, Daniela Denisse
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date: 2019
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Moye Holz, D. D. (2019). Access to innovative medicines in a middle-income country: The case of Mexico and cancer medicines. Rijksuniversiteit Groningen.
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
221 About the Author
AA
Daniela Moye Holz is a global health researcher with a focus on the pharmaceutical field and access to medicines. She has worked in several stages of the life cycle of pharmaceutical products – from research and development, production, pharmaceutical policies and access to medicines. Her research interests include pharmaceutical and health systems policies, access to medicines, and access to health innovation and health technologies. Daniela holds a Bachelor in Science in Pharmaceutical and Biological Chemistry from the National Autonomous University of Mexico (UNAM) (Mexico); a Masters in Science in International Health from the Ruprecht-Karls-Universität Heidelberg (Germany); and a Ph.D. in Global Health from the University of Groningen (Netherlands).
Her professional experience started in the pharmaceutical production facilities of Novartis Pharmaceuticals in Mexico. She continued her professional development at a leading Clinical Research Organization, PPD Inc., where she became a clinical research associate for diverse clinical trials and clients. After her master’s degree, Daniela started her Ph.D. research at the University Medical Center Groningen of the University of Groningen. She has carried out pharmaceutical policy analysis and measured their effects on access to medicines. Outcomes from this research include five research manuscripts, a policy brief (in process) and a book chapter (in process). Her published work has gained interest from the media. The Mexican National Council for Science and Technology (CONACYT) and SciDevNet have interviewed and published articles related to her work on Mexican pharmaceutical policies and access to innovative medicines.
Publications:
Moye-Holz D, van Dijk JP, Reijneveld SA, Hogerzeil HV. Policy approaches to improve availability and affordability of medicines in Mexico - an example of a middle-income country. Global Health. 2017 Aug 1;13(1):53. doi: 10.1186/s12992-017-0281-1.
Moye-Holz D, Soria Saucedo R, van Dijk JP, Reijneveld SA, Hogerzeil HV. Access to Innovative Cancer Medicines in a Middle-Income Country - the case of Mexico. Journal of Pharmaceutical Policy and Practice. 11, 25. doi: 10.1186/s40545-018-0153-y
